Enveric Biosciences Granted US Patent for Innovative Mental Health Therapies

Enveric Biosciences, a biotechnology company developing innovative neuroplastogenic small-molecule therapeutics for psychiatric and neurological conditions, has announced the issuance of US Patent No. 12,492,179, titled “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives” (the ‘179 patent). The patent covers compositions and treatment methods for new molecules with potential applications in mental health therapies.

The ‘179 patent broadens protection for Enveric’s pipeline of potentially neuroplastogenic, non-hallucinogenic molecules, enhancing the company’s ability to address neuropsychiatric, neurological, and addiction disorders in patients with limited treatment options. By targeting key receptors in novel ways, these molecules could lead to drug candidates with improved efficacy and safety profiles. The expanded portfolio also opens doors for licensing and partnerships with pharmaceutical companies investing in neuropsychiatric therapeutics.

Strong intellectual property protection is a critical factor for pharmaceutical companies considering long-term clinical development, as it ensures a viable return on investment. Composition-of-matter patents, like the ‘179 patent, represent one of the strongest forms of IP protection for novel molecules.

The molecules under the ‘179 patent are derived from known compounds with relevant pharmacological activity but are chemically modified to enhance efficacy and reduce side effects. These innovations have the potential to outperform existing treatments for neuropsychiatric disorders.

Enveric Biosciences continues to focus on advancing small-molecule neuroplastogenic therapeutics that promote neuroplasticity without hallucinogenic effects, leveraging a differentiated drug discovery platform and a growing library of patent-protected chemical structures.

Also Read